November 20, 2020

VIA ELECTRONIC SUBMISSION

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

CITIZENS PETITION – WITHDRAWAL REQUEST

RE: FDA-2020-P-2013

Dear Sir or Madam:

Lachman Consultant Services, Inc. hereby requests to withdraw the Citizen Petition submitted on September 25, 2020; assigned Docket number FDA-2020-P-2013.

The Citizen Petition was submitted pursuant to the Federal Food, Drug and Cosmetic Act ("FDC Act") and in accordance with 21 C.F.R. §§ 10.25(a) and 10.30 to request that FDA amend the *Approved Drug Products with Therapeutic Equivalence Evaluations* ("Orange Book") to designate Lidocaine Hydrochloride Topical Jelly, 2%, approved under Abbreviated New Drug Application ("ANDA") 040433, as a new Reference Standard ("RS").

Please advise if additional information is required in order to complete withdrawal of FDA-2020-P-2013.

Sincerely,

Michelle R. Ryder
Michelle R. Ryder
cn=Michelle R. Ryder, o=Lachman Consultant Services, Inc., ou, email=m.ryder@lachmanconsultants.com, c=US
2020.11.20 15:09:40 -07'00'

Michelle R. Ryder
Principal Consultant
Lachman Consulting Services, Inc.